Comparative Review of PLGA and Chitosan Nanoparticles for Pharmaceutical Applications

Nanotechnology has revolutionized the pharmaceutical industry, offering advanced solutions for drug delivery, targeting, and controlled release. Among the various materials explored, Poly(lactic-co-glycolic acid) (PLGA) and Chitosan have emerged as prominent candidates due to their unique properties and versatile applications. This article reviews and compares the characteristics, advantages, and applications of PLGA and Chitosan in the realm of pharmaceutical nanotechnology, supported by recent research findings.

Poly(lactic-co-glycolic acid) (PLGA)

1. Biocompatibility and Biodegradability: PLGA is a copolymer of lactic acid and glycolic acid, renowned for its excellent biocompatibility and biodegradability. It degrades into lactic acid and glycolic acid, which are metabolized by the body, minimizing toxicity and adverse effects .

2. Controlled Release: One of the significant advantages of PLGA is its ability to provide controlled and sustained release of therapeutic agents. By varying the ratio of lactic acid to glycolic acid, the degradation rate and, consequently, the drug release profile can be finely tuned .

3. Drug Encapsulation Efficiency: PLGA nanoparticles exhibit high drug encapsulation efficiency, protecting the encapsulated drug from degradation and enhancing its stability. This is particularly beneficial for sensitive biologics and poorly soluble drugs .

4. Versatility: PLGA can be processed into various forms, including nanoparticles, microparticles, and implants, making it versatile for different drug delivery applications. Its surface can also be modified to enhance targeting capabilities .

Applications:

• Cancer Therapy: PLGA nanoparticles have been extensively studied for delivering chemotherapeutic agents, providing targeted and controlled drug release, reducing systemic toxicity .
• Vaccines: PLGA-based systems enhance the delivery and stability of antigens, improving the immune response .
• Tissue Engineering: PLGA scaffolds support cell growth and tissue regeneration, making them suitable for tissue engineering applications .

Chitosan

1. Natural Polymer: Chitosan is a natural polysaccharide derived from chitin, found in the exoskeleton of crustaceans. It is biocompatible, biodegradable, and non-toxic, making it an attractive material for pharmaceutical applications .

2. Mucoadhesive Properties: Chitosan exhibits excellent mucoadhesive properties, allowing for prolonged retention at mucosal sites. This enhances the absorption of drugs across mucosal membranes, making it ideal for oral and nasal drug delivery .

3. Biodegradability: Chitosan is degraded by lysozymes present in the body, producing non-toxic byproducts. Its biodegradability can be controlled by modifying its molecular weight and degree of deacetylation .

4. Antimicrobial Activity: Chitosan possesses inherent antimicrobial properties, which can be advantageous for wound healing and preventing infections in drug delivery systems .

Applications:

• Oral Drug Delivery: Chitosan nanoparticles enhance the oral bioavailability of poorly absorbed drugs by protecting them from degradation and improving mucosal absorption .
• Gene Delivery: Chitosan’s positive charge facilitates the formation of complexes with negatively charged DNA, improving gene delivery efficiency .
• Wound Healing: Chitosan-based dressings promote wound healing due to their antimicrobial properties and ability to support cell proliferation .

Comparison and Conclusion

While both PLGA and Chitosan are valuable materials in pharmaceutical nanotechnology, they offer distinct advantages tailored to different applications.

• Biocompatibility and Biodegradability: Both materials are biocompatible and biodegradable, but PLGA offers more controlled degradation rates, making it suitable for long-term drug release applications .
• Drug Release and Encapsulation: PLGA excels in controlled and sustained drug release, whereas Chitosan’s mucoadhesive properties make it ideal for enhancing drug absorption at mucosal sites .
• Versatility: PLGA is highly versatile in its applications, from cancer therapy to tissue engineering, while Chitosan’s natural origin and antimicrobial properties offer unique advantages for oral drug delivery and wound healing .
• Processing and Modification: PLGA’s synthetic nature allows precise control over its properties, whereas Chitosan’s natural origin may require more extensive modification for specific applications .

In conclusion, the choice between PLGA and Chitosan depends on the specific requirements of the pharmaceutical application. PLGA’s controlled release capabilities and versatility make it a preferred choice for many drug delivery systems, while Chitosan’s natural properties and mucoadhesiveness offer unique benefits for enhancing drug absorption and wound healing. Future research and development will continue to optimize these materials, expanding their potential in pharmaceutical nanotechnology.

References

1. Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel). 2011;3(3):1377-1397.
2. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505-522.
3. Giri TK, Thakur A, Alexander A, Ajazuddin, Badwaik H, Tripathi DK. Modified chitosan hydrogels as drug delivery and tissue engineering systems: present status and applications. Acta Pharm Sin B. 2012;2(5):439-449.
4. Muthu MS, Rawat MK, Mishra A, Singh S. PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomedicine. 2009;5(3):323-333.
5. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21(5):387-422.
6. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505-515.
7. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55(3):329-347.
8. Zolnik BS, Burgess DJ. Evaluation of in vivo release of dexamethasone from PLGA microspheres. J Control Release. 2008;127(2):137-145.
9. Dash M, Chiellini F, Ottenbrite RM, Chiellini E. Chitosan—A versatile semi-synthetic polymer in biomedical applications. Prog Polym Sci. 2011;36(8):981-1014.
10. Akhlaq M, Zia KM, Akash MS, Adnan S, Salmieri S, Lacroix M. Biodegradable poly(lactic-co-glycolic acid)-based biomaterials: Synthesis and biomedical applications. J Control Release. 2017;259:412-429.
11. Jayakumar R, Prabaharan M, Sudheesh Kumar PT, Nair SV, Tamura H. Biomaterials based on chitin and chitosan in wound dressing applications. Biotechnol Adv. 2011;29(3):322-337.
12. Rinaudo M. Chitin and chitosan: properties and applications. Prog Polym Sci. 2006;31(7):603-632.
13. Vila A, Sánchez A, Tobío M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release. 2002;78(1-3):15-24.
14. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283-318.
15. Felt O, Buri P, Gurny R. Chitosan: a unique polysaccharide for drug delivery. Drug Dev Ind Pharm. 1998;24(11):979-993.